Thursday, February 18, 2016

Pliant Therapeutics Gets $45M

Redwood City-based Pliant Therapeutics, a new company focused on treatments for fibrotic diseases of the lungs, has raised $45M in a Series A funding. The funding came from Third Rock Ventures. Plaint has named Bernard Coulie, M.D., Ph.D. as its CEO. Coulie was most recently the CEO of ActoGeniX. Third Rock and Pliant said that the company is developing new therapies to treat the pathologic process of fibrotic disorders.